

Ana Martinez-Naharro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8902281/publications.pdf>

Version: 2024-02-01

43
papers

2,809
citations

304743

22
h-index

315739

38
g-index

43
all docs

43
docs citations

43
times ranked

2200
citing authors

#	ARTICLE	IF	CITATIONS
1	A new staging system for cardiac transthyretin amyloidosis. <i>European Heart Journal</i> , 2018, 39, 2799-2806.	2.2	396
2	Magnetic Resonance in Transthyretin Cardiac Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 466-477.	2.8	290
3	Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. <i>Circulation</i> , 2019, 140, 16-26.	1.6	288
4	Native T1 and Extracellular Volume in Transthyretin Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 810-819.	5.3	172
5	Myocardial Edema and Prognosis in Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2919-2931.	2.8	145
6	Automated Pixel-Wise Quantitative Myocardial Perfusion Mapping by CMR to Detect Obstructive Coronary Artery Disease and Coronary Microvascular Dysfunction. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1958-1969.	5.3	140
7	Cardiac amyloidosis. <i>Clinical Medicine</i> , 2018, 18, s30-s35.	1.9	135
8	Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 69-80.	5.3	125
9	Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 1344-1350.	1.2	124
10	Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 823-833.	5.3	113
11	Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 189-199.	5.3	113
12	Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. <i>European Heart Journal</i> , 2020, 41, 1439-1447.	2.2	108
13	CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 152-154.	5.3	90
14	Diagnostic imaging of cardiac amyloidosis. <i>Nature Reviews Cardiology</i> , 2020, 17, 413-426.	13.7	84
15	Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 17-29.	5.3	67
16	High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1733-1734.	2.8	65
17	Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. <i>European Heart Journal</i> , 2022, 43, 333-341.	2.2	45
18	Prospective comparison of novel dark blood late gadolinium enhancement with conventional bright blood imaging for the detection of scar. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 19, 91.	3.3	36

#	ARTICLE	IF	CITATIONS
19	Assessment of Multivessel Coronary Artery Disease Using Cardiovascular Magnetic Resonance Pixelwise Quantitative Perfusion Mapping. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2546-2557.	5.3	30
20	Analysis of the <i>TTR</i> gene in the investigation of amyloidosis: A 25-year single UK center experience. <i>Human Mutation</i> , 2019, 40, 90-96.	2.5	29
21	Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance. <i>Scientific Reports</i> , 2019, 9, 1388.	3.3	27
22	Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. <i>European Heart Journal</i> , 2022, 43, 2622-2632.	2.2	27
23	Diffusion Tensor Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e009901.	2.6	26
24	Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. <i>ESC Heart Failure</i> , 2020, 7, 3942-3949.	3.1	22
25	Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities. <i>Journal of the American Heart Association</i> , 2019, 8, e012097.	3.7	21
26	Quantitative cardiovascular magnetic resonance myocardial perfusion mapping to assess hyperaemic response to adenosine stress. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 273-281.	1.2	15
27	001â€¦Multiparametric mapping to understand pathophysiology in cardiac amyloidosis. <i>Heart</i> , 2017, 103, A1-A2.	2.9	12
28	Staging Cardiac Amyloidosis With CMR. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 1278-1279.	5.3	10
29	The value of screening biopsies in lightâ€chain (AL) and transthyretin (ATTR) amyloidosis. <i>European Journal of Haematology</i> , 2020, 105, 352-356.	2.2	10
30	A case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid. <i>BMC Medical Imaging</i> , 2017, 17, 3.	2.7	9
31	Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. <i>Heart</i> , 2022, 108, 474-478.	2.9	8
32	Extracellular volume with bolusâ€only technique in amyloidosis patients: Diagnostic accuracy, correlation with other clinical cardiac measures, and ability to track changes in amyloid load over time. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 1677-1684.	3.4	7
33	Distinct cardiovascular phenotypes are associated with prognosis in systemic sclerosis: a cardiovascular magnetic resonance study. <i>European Heart Journal Cardiovascular Imaging</i> , 2023, 24, 463-471.	1.2	7
34	028â€¦Routine identification of hypoperfusion in cardiac amyloidosis by myocardial blood flow mapping. <i>Heart</i> , 2017, 103, A24-A24.	2.9	3
35	Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin lightâ€chain (AL) amyloidosis. <i>British Journal of Haematology</i> , 2021, 194, 1016-1023.	2.5	3
36	Atrial Involvement in Cardiac Amyloidosis. <i>JACC: CardioOncology</i> , 2020, 2, 732-734.	4.0	3

#	ARTICLE	IF	CITATIONS
37	Reply. Journal of the American College of Cardiology, 2018, 72, 1881.	2.8	2
38	Detailed Understating of Cardiac Amyloidosis by CMR. JACC: Cardiovascular Imaging, 2020, 13, 1311-1313.	5.3	1
39	The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis. Blood, 2020, 136, 40-40.	1.4	1
40	Spectrum and significance of CMR findings in cardiac transthyretin amyloidosis. Heart, 2017, 103, A20-A21.	2.9	0
41	Demonstration of cardiac AL amyloidosis regression after succesful chemotherapy. a CMR study. Heart, 2017, 103, A7.1-A7.	2.9	0
42	Treatment response in cardiac al amyloidosis assessed by CMR: findings at 3 months, 6 months and 1 year post-chemotherapy. , 2018, , .		0
43	Myocardial perfusion mapping in cardiac amyloidosis- unearthing the spectrum from infiltration to ischaemia. , 2019, , .		0